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ScreeningMany patients with cardiovascular disease have their low density lipoprotein cholesterol within normal
range. This raises the question about the most important lipoprotein to use as a marker of atherogenecity.
In fact, small dense low density lipoprotein has recently been suggested as a strong predictor of cardio-
vascular disease. Among high risk patients, those with metabolic syndrome represent an important target
population.
Different methods of small dense low density lipoprotein measurement were developed. Accordingly,
two phenotypes of low density lipoprotein are recognized: Phenotype A (predominance of large buoyant
low density lipoprotein) & phenotype B (predominance of small dense low density lipoprotein). However,
none of the methods has been yet considered as a gold standard one. A lot of studies confirmed the role of
small dense low density lipoprotein in the development of cardiovascular disease through atherogenic
properties & clinical trials. However, others failed to do so. These discrepancies may be due to different
sample sizes, different populations, different age groups, different methods of measurement & other pos-
sible confounding factors.
The aim of this review is to discuss the role of small dense low density lipoprotein as a valuable screen-
ing/preventive tool of cardiovascular disease in patients with metabolic syndrome.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
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1.1. Cardiovascular diseases: Definition and epidemiological studies
Cardiovascular diseases (CVD) include any medical conditions
concerning the heart and blood vessels; such as coronary heart dis-
ease (CHD), strokes, peripheral vascular disease (PVD), and abdom-
inal aortic aneurysm (AAA). Cardiovascular diseases are the main
cause of morbidity and mortality worldwide. About 17.5 million
people died from CVD in 2005. Among them, 7.6 million deaths
were due to CHD and 5.7 million were due to stroke. We should
be careful as regards progression of CVD, because about 20 million
CVD deaths were estimated in 2015.1 Many studies suggest that
metabolic syndrome (MetS/MS) cases are more liable for future
development of CHD and type 2 diabetes mellitus (T2DM).2
1.2. Definition of metabolic syndrome
Different definitions of MetS were established. According to
National Cholesterol Education Program: Adult Treatment Panel
III (NCEP: ATP III), MetS is defined by three or more of the follow-
ing: waist circumference <_102 cm in men (or >_88 cm in women),
triglycerides >_150 mg, high density lipoprotein (HDL) <40 mg/dl
in men (or <50 mg/dl in women), fasting plasma glucose
>_110 mg/dl, blood pressure >_130/85 mmHg.3,4 According to the
World Health Organization (WHO): Metabolic syndrome is defined
by insulin resistance (identified by 1 of the following: T2DM,
impaired fasting glucose, impaired glucose tolerance or for those
with normal fasting glucose levels (<110 mg/dl), glucose uptake
lower than the lowest quartile for background population under
investigation under hyperinsulinemic, euglycemic conditions) plus
any two of the following parameters: body mass index (BMI)
> 30 kg/m2, waist–hip ratio (WHR) > 0.9 in men (or >0.85 in
women), triglycerides >_150 mg/dl, low HDL (<35 mg/dl in men
or <39 mg/dl in women), blood pressure >_140/90 mmHg or
antihypertensive medication, urinary albumin excretion rate
>_20 lg/min or albumin:creatinine ratio >_30 mg/g.5 Metabolic
syndrome can be defined (according to the International Diabetes
Federation (IDF)) by obesity, given as waist circumference
<_94 cm in men (or <_80 cm in women) for Europeans, plus at least
two of the following parameters: triglycerides <_150 mg/dl or
treatment for hypertriglyceridemia, HDL < 40 mg/dl in men
(or <50 in women) or treatment for this lipid abnormality,
fasting plasma glucose (mg/dl) > 100 or diagnosis of diabetes
mellitus, blood pressure <_130/85 mmHg or treatment for
hypertension.3 It should be noted that a lot of cases of metabolic
syndrome are asymptomatic. They only present lately by
symptoms of diabetes.6
1.3. Low density lipoprotein subclasses, phenotypes, reference values
and methods of measurement
Some studies have shown that the use of hypolipidemic agents
reduces CVD risk through the modification of Low density lipopro-tein (LDL) particle size; however, the use of statins was associated
with reduction rates of CVD less than 30%. To get better reduction
rates, we should concentrate on the ‘‘beyond cholesterol” concept.
Low density lipoprotein particles include three subclasses (LDL
I–III), LDL I (large buoyant LDL), LDL II (intermediate density LDL),
and LDL III (smaller dense LDL). Different laboratory procedures
can be used to separate LDL subclasses. Among them ultracentrifu-
gation and electrophoresis have been mostly used for determining
LDL subclasses. However, none of these methods has been estab-
lished as a ‘‘gold standard” one.7,8
In fact, Gradient Gel electrophoresis (GGE) was considered as an
important criteria of CHD risk. However, there is inadequate evi-
dence that LDL subclassification by GGE improves outcomes in
patients with CV disease.
Besides, as regards Density Gradient Ultracentrifugation (DGU),
the Vertical Auto Profile (VAP) test measures the relative distribu-
tion of cholesterol within various lipoprotein subfractions, quanti-
fying the cholesterol content in the VLDL, IDL, LDL, lipoprotein(a)
and HDL subclasses. It includes LDL density and other components
(i.e.pattern A versus pattern B).9
Concerning Nuclear Magnetic Resonance Spectroscopy (NMR),
FDA clearance of NMR does not mean the test has clinical impor-
tance.9 However, according to Mehta et al., measuring sdLDL by
NMR were shown to be a strong predictor of CV events.10
In addition, the Ion-Mobility Analysis measures both the size
and concentration of lipoprotein particle subclasses on the basis
of gas-phase differential electric mobility.9
According to LDL particle size and density, the human lipid pro-
file can be classified into two phenotypes: pattern A and pattern B.
Pattern A is characterized by predominance of large buoyant LDL
(LDL > 25.5 nm) and pattern B is characterized by predominance
of small dense LDL (LDL  25.5 nm).1,11,12
Small dense low density lipoprotein (sdLDL) phenotype is
expressed in adulthood as a result of genetic and environmental
factors. Dyslipidemia, obesity and insulin resistance lead to expres-
sion of phenotype B.4,12 For a given triglyceride level, women were
found to have less sdLDL than men. On the other side, Korean
males have a greater tendancy to develop a sdLDL phenotype than
their Western counterparts.132. Atherogenic properties of small dense low density
lipoprotein
Many experimental studies have explained the atherogenic
properties of sd-LDL particles. Small dense low density lipopro-
tein particles have small size which enables them to penetrate
easily into the arterial wall. They have also a high affinity for pro-
teoglycans in the arterial wall, leading to prolonged residency in
the subendothelial space.4,8,14,15 Besides, the affinity of sd-LDL for
LDL receptors is lower than larger LDL particles and its clearance
from plasma is delayed.4,14–17 Small dense low density lipoprotein
particles are deficient in vitamin E and are highly susceptible to
oxidization.4,7,8,14,15 All these features explain the increased
atherogenicity of small LDL subclasses.1,7,8,13,18–20
Table 1
Small dense low density lipoprotein as a predictor for cardiovascular disease.
Investigator/type
of the study
Duration Sample size Results Advantages Limitations Conclusion
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and the presence of oxidized LDL to endothelial function as
assessed by the response in forearm blood flow to acetylcholine,
bradykinin, and sodium nitroprusside. The acetylcholine response
was positively associated with LDL size and negatively correlated
with the plasma level of oxidized LDL.13
However, antioxidant strategies failed to prevent and to limit
the atherogenesis in humans. This raised questions about the role
of oxidative modification of LDL in atheromatosis.1
Another proposed mechanism suggest that: sd-LDL may induce
the stimulation of plasminogen-activator-inhibitor 1 and acceler-
ate thromboxane A2 synthesis.73. Small dense low density lipoprotein as a predictor for
cardiovascular disease
Small dense low density lipoprotein is considered an important
emerging risk factor for CVD.1,8,21
In an observational cohort study (details shown in Table 1),
patients who developed cardiovascular events had higher sd-LDL
level, sd-LDL/LDL ratio, LDL/HDL ratio & greater HbA1c. Cardiovas-
cular events were death caused by CVD, onset of acute coronary
syndrome (ACS), need for peripheral arterial and coronary revascu-
larization, hospitalization for surgical procedure for any CVD,
hospitalization for heart failure and/or for stroke. Those who
experienced cardiovascular events were older, had higher preva-
lence of hypertension (HT) and diabetes mellitus (DM), significant
higher Gensini coronary atherosclerosis scores. In conclusion, these
results confirmed that sdLDL is a very promising biomarker to
predict future cardiovascular events in the secondary preven-
tion of stable coronary artery disease (CAD).20 However, the Kor-
ean Health and Genome Study (KHGS, a prospective cohort study)
reported that DM was the only independent predictive factor of
CVD.22 The KHGS was conducted on a larger sample size and for a
longer duration, compared to the study conducted by Nishikura
et al. However, the KHGS study was limited to the Korean popu-
lation, the samples might be altered and data on the use of lipidlowering agents were lacking. Therefore, the results should be
confirmed by larger prospective cohort studies and randomized
controlled trials (RCTs), with a better methodology. The results
of these studies are further discussed in Table 1.
Also, according to a meta-analysis of twelve RCTs, a residual risk
of major cardiovascular events was demonstrated despite usage of
hypolipemic agents (statins).23 This raises the question about the
role of fibrates which target specifically the sdLDL.
Besides, according to a longitudinal observational study, Small
dense LDL cholesterol is a cardiovascular risk factor in several
chronic inflammatory diseases.244. Clinical significance of small dense low density lipoprotein in
coronary heart disease
Low Density Lipoprotein-Cholesterol (LDL-C) concentration is
not always elevated in patients with ACS.16
Studies have shown that a predominance of sd-LDL is closely
associated with CAD. Also, sd-LDL-cholesterol (small density LDL-
cholesterol) concentrations are high in individuals at a high risk
for CAD, including patients with T2DM and MS. Therefore, sd-
LDL concentration is considered as a surrogate marker for CAD
and is accepted as a risk factor for cardiovascular events by the
(NCEP III).7,8,12,15,25 Similar results were found in case-control
and prospective studies.11
In a case-control study, the serum sdLDL was detected in 146
CAD patients + 207 control group using the heparin-Mg precipita-
tion method. The 26.8% of CAD patients with LDL-C < 2.59 mmol/l
have serum sdLDL-C > 0.62 mmol/l, and they are characteristic of
higher total cholesterol, triglycerides and lower HDL-C. They con-
cluded that the measurement of serum sd-LDL is valuable in
explaining the residual cardiovascular risk in patients with CAD,
especially those with DM.26
A case-control study was conducted on 194 consecutive
patients with chest pain (which is considered of low to intermedi-
ate risk for significant coronary stenosis) who were referred for
elective coronary angiography. The proportion of sdLDL was a
Table 2
Clinical significance of small dense low density lipoprotein in CHD.
Investigator/type
of the study
Duration Sample size Results Advantages Limitations Conclusion
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evaluated by both methods: invasive coronaryangiography & CT
based techniques. It was concluded that sdLDL particles may play
a role in risk classification of patients with suspected angina
pectoris.19
Findings from the Quebec Cardiovascular Study confirmed
that sdLDL (LDLc < 255 Å) is a strong and independent predictor
of CHD in the first seven years of follow up.1,13,20,27
Ai et al. quantified sd-LDL-C in 1680 female participants of the
Framingham Offspring Studywith or without CHD. Mean sd-LDL-
C levels were higher in those with CHD compared to those without
CHD (0.83 vs. 0.68 mmol/L, P = 0.0015) although they had the sim-
ilar mean LDL-C levels (3.53 vs. 3.46 mmol/L, P = 0.543). Thus, sd-
LDL-C measurement helps in the management of high-risk patients
with CADwhose total LDL-C levels are not elevated. Unlike women,
1508 men with or without CHD in the same study had similar
levels of mean sd-LDL-C (0.83 vs. 0.84 mmol/L, P = 0.609). How-
ever, the percentage of sd-LDL-C to total LDL-C was higher in those
with CHD than in those without CHD (26.1% vs. 23.7%, P = 0.0019).
This could be explained by the fact that men generally had more
confounding factors than women, the ratio of sd-LDL-C to total
LDL-C may be more valuable than the absolute concentration of
sd-LDL-C.7,28
In a prospective cohort study, (the biracial ARIC study) plasma
sdLDL-C levels were strongly correlated with an atherogenic lipid
profile and were higher in diabetic patients than non-diabetic
patients (49.6 versus 42.3 mg/dL; P < 0.0001). Even in individuals
considered to be at low cardiovascular risk based on their LDL-C
levels, the sdLDL-C was associated with incident CHD in
atherosclerosis risk in communities (ARIC) study participants.29
All of the previous studies confirmed the role of sdLDL as a predic-
tor of CHD. However, The Framingham Offspring study showed
that sdLDL /LDL ratio is a very strong predictor of CHD in men;
this might be attributed to the fact that men had more confound-
ing factors. These studies are further discussed in Table 2, taking
into account the sample size, the gender, the duration of the
study, the method of measurement, other possible confounding
factors and the P value of the results. Besides, lipoprotein profiles
that are relatively rich in sd-LDL particles are associated with up toa 3-fold greater risk of myocardial infarction than those that
mainly consist of large buoyant (lb)-LDL particles.1,17
5. Clinical significance of small dense low density lipoprotein in
cerebrovascular strokes
Acute ischemic stroke (AIS) is an important cause of morbidity
and mortality worldwide. In fact, logistic regression analysis
showed that increased sdLDL was an important predictor for
AIS onset even when the other CVD risk factors were taken into
consideration. Thus, it was concluded that measuring LDL particle
size alone is not sufficient for accurate assessment of AIS risk.15,30
Zeljkovic et al. reported, according to Landray et al. study, a
greater proportion of smaller LDL subfractions in cases with carotid
atherosclerosis than in those with normal carotid arteries. Also,
smaller LDL particles were associated with risk for carotid
atherosclerosis.15,31
However, Zeljkovic et al. reported in a prospective cohort study
analysis (including 200 patients and 162 controls) that patients
who experienced strokes had a higher level of sdLDL (P < 0.001).
It also reported that early AIS mortalities had significantly higher
amount of sdLDL particles (P < 0.05), underlining the impor-
tance of sdLDL during disease exacerbation. An AIS patient with
elevated level of sdLDL had 5.5-fold higher risk of dying during
hospitalization, even when other confounding factors were
adjusted. The limitations of this study were that: cases and con-
trols weren’t matched by the age and the sex, the number of cases
of mortality was limited and the population was limited (Serbian
population).15
So, sdLDL is an independent very strong predictor of incidence
of cerebrovascular strokes. Also, it’s a strong predictor of mortality
by cerebrovascular strokes.
Furthermore, sdLDL-C may be a useful predictor in the assess-
ment of CA-IMT in Chinese population: there was significant asso-
ciation between them after adjustment of traditional CVD risk
factors. In addition, sdLDL was considered a better lipid variable
than other standard parameters in assessing the risk of CVD using
CA-IMT in healthy population. The limitations of this study were
that: the cohort was relatively small and included only the healthy
R.M.A. Zaki Khalil et al. / Alexandria Journal of Medicine 53 (2017) 299–305 303subjects. Subjects with coronary risk factors or CVD are required.
Finally, it is not possible to determine a cause and effect relation-
ship between sdLDL-C concentrations and CA-IMT as this study
was a cross-sectional one. Therefore, further studies are needed.326. Metabolic syndrome: an important target population
MetS is considered a major risk factor for CVD.4 According to the
American Association of Clinical Endocrinologists (AACE), patients
with metabolic syndrome are at increased risk of cardiovascular
disease.33
6.1. Risk assessment
The 10-year risk of fatal cardiovascular disease (death caused
by any arterial disease) can be estimated using the Systematic Cor-
onary Risk Evaluation (SCORE) system. According to the European
Society of Cardiology (ESC), the 2012 guidelines for cardiovascu-
lar prevention established that patients can be classified into four
major groups: low risk (with a SCORE rating less than 1%, corre-
sponding to a 10-year probability of cardiovascular mortality of
less than 1%), moderate risk (with a SCORE greater or equal to 1%
and less than 5%), high risk (subjects with markedly elevated one
risk factor, as well as subjects with diabetes, moderate chronic kid-
ney disease, or a SCORE rating greater or equal to 5% and less than
10%) and very high risk (those with documented cardiovascular
disease, severe chronic kidney disease, diabetes associated with
one (or more) cardiovascular risk factor(s), diabetes with eGFR
(estimated glomerular filtration rate) less than 60 mL/min/1.73 m2
or subjects with a SCORE rating greater or equal to 10%).21
6.2. Formation & significance of small dense low density lipoprotein in
metabolic syndrome
Studies have demonstrated that pattern B lipid profile is associ-
ated with a dyslipidaemic syndrome (ALP: atherogenic lipid pro-
file) which is characterized by elevated levels of large triglyceride-
rich very low density lipoproteins (VLDL), low HDL levels, high
levels of small dense LDL, and high hepatic lipase activity. The
overproduction or the decreased clearance of VLDL is the key meta-
bolic feature of the generation of sdLDL. These features are com-
mon in patients with diabetes and metabolic syndrome.3,13
Patients with insulin resistance (IR) and central obesity exhi-
bit increased lipolysis and elevated levels of free fatty acids. This is
the main feature in the pathophysiology of metabolic syndrome.3
Triglyceride levels and obesity are important factors that affect
LDL particle size. In case of hypertriglyceridemia, Triglycerides are
transferred from VLDL to HDL, then to LDL; while cholesterol is
eliminated from LDL. This leads to the formation of smaller denser
LDL.12
The generation of sdLDL particles seems to be related to the
insulin resistance and hypertriglyceridemia; this can contribute
to the significance of sdLDL in patients with the metabolic
syndrome.34
6.3. Small dense low density lipoprotein as a predictor for
cardiovascular disease in patients with metabolic syndrome
Accumulating evidence has shown that sd-LDL levels are
increased in atherosclerotic disorders, including diabetes, dyslipi-
demia, MetS and cardiovascular disease.1,7,8,16,18
In a prospective 2-year follow-up study, conducted on subjects
with metabolic syndrome and without overt CAD, sdLDL was found
as a feature of the metabolic syndrome and an independent predic-
tor for future cardio- and cerebro-vascular events. These findingsmay have potentially important consequences on the assessment
and management of atherogenic dyslipidemia in this category of
high-risk patients but should be confirmed by future prospective
studies with larger sample size.25
According to the Framingham Heart Study, small LDL particle
concentration augmented with the number of metabolic syndrome
features and patients with the metabolic syndrome were more
prone to cardiovascular events. However, it didn’t succeed to prove
a significant association between the concentration of small LDL
and risk of cardiovascular disease. The discrepancy of this result
with that in the Quebec study may be attributed to the loss of
the discriminatory power of sdLDL in this group of high-risk sub-
jects.13,35 However, another study revealed that LDL particle size
is rarely a significant and independent predictor of CAD risk in
patients without MetS.4
Also, Packard et al. reported that, according to a multivariate
analysis conducted by Berneis et al., LDL size is the variable most
strongly linked to the presence of CHD and to a positive carotid
intima media thickness (IMT) measurement (>1-mm thick-
ness).13,36 Similar results were reported by Gerber et al.34 There-
fore, the previous studies confirmed the role of sdLDL as a
component of metabolic syndrome cases, as a predictor for insu-
lin resistance, IMT and cardiovascular events in patients with
MetS. However, the duration of these studies might be insuffi-
cient, selection bias cannot be excluded and the results should
be confirmed by larger prospective cohort studies, and RCTs.
Details are shown in Table 3.
In an observational study including 185 patients from South of
Spain, it was reported that LDL particle size was smaller in males
than females and that LDL particle size was smaller in patients
with MetS than in patients without MetS. According to this study,
predominance of sdLDLc was associated with an increased risk of
CAD.4
Many studies have demonstrated an increased cardiovascular
risk in patients with MS even before the development of overt
hyperglycemia. An increase in sdLDL particles is strongly associ-
ated with an increased cardiovascular risk, both in patients with
and without diabetes or metabolic syndrome, even when the tradi-
tional risk factors were taken into consideration.34
Besides, in a case-control study, the serum sdLDL-C in the
patients with CAD and T2DM is significantly higher than that
in the CAD without T2DM, 0.48 mmol/l versus 0.42 mmol/l,
p < 0.05). It was concluded that the detection of serum sd-LDL
could help in understanding the residual cardiovascular risk in
patients with CAD, particularly when associated with DM.26
Similar results were found in a prospective cohort study: sdLDL
level was measured in the biracial ARIC study using a new devel-
oped homogenous assay. Plasma sdLDL-C levels were strongly cor-
related with the dyslipidemic syndrome and were higher in
patients with diabetes mellitus than non-diabetes mellitus (49.6
versus 42.3 mg/dL; P < 0.0001).29 Furthermore, Hirayama et al.
reported, according to Toledo et al.’s study, that cases with type
2 diabetes (associated to moderate or severe hepatic steatosis)
had 25% and 72% higher sd-LDL concentrations than those without
hepatic steatosis.7,37
Moreover, patients with metabolic syndrome or type 2 diabetes
have an increased cardiovascular risk despite optimal control of
other risk factors as LDL-C.34 In addition, Inukai et al. study found
that the strongest predictor of carotid artery IMT in 27 diabetic and
12 control subjects was the concentration of small LDL, indepen-
dent of LDL size distribution, LDL cholesterol, HDL cholesterol or
triglyceride.13 Similar results were found by a prospective cohort
study.34
In addition, a group of reports described the associations of sd-
LDL with many metabolic disorders, such as endocrine diseases,
including growth hormone (GH) deficiency, polycystic ovary syn-
Table 3
SdLDL as a predictor for CVD in patients with metabolic syndrome.
Investigator/type
of the study
Duration Sample size Results Advantages Limitations Conclusion
Rizzo et al. 2 years 732 cases of
MetS, without
overt CAD
sdLDL is a feature of MetS, and an
independent predictor for future
cardiovascular and cerebrovascular
events (P < 0.0001)
– Large sam-
ple size





sdLDL is a very promising
screening tool of cardiovascular
events in patients with MetS
Prospective
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and insulin resistance (IR) (P < 0.05)
Sancho-Rodiguez
et al.




– LDL particle size was significantly
smaller in MetS patients (P > 0.001)
– Predominance of sdLDL was associ-












sdLDL is an important
component of MetS, and a








– MetS cases had a higher level of
sdLDL (P = 0.042), and a higher rate
of cardiovascular events
(P = 0.0202: for stable angina,
P = 0.0893: for acute coronary
syndrome)
– However, there was no discernable
association between the abundance













– Results should be con-
firmed by further investiga-
tions taking into account
the modified Japanese crite-
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human immunodeficiency virus (HIV) infection.7
However, the various study documented that elevated LDL-C
and increased ratio of LDL/HDL is the most valuable lipid param-
eter making those individuals at risk for atherosclerosis.1
7. Conclusion
Small dense low density lipoprotein is a new emerging risk fac-
tor for cardiovascular diseases because it is more atherogenic than
LDL. It can be used as a predictor of future cardiovascular events
and in secondary prevention of stable coronary artery disease.
sd-LDL can also predict mortality from AIS. It was found that
patients with AIS who had elevated sd-LDL had 5.5-fold higher risk
of dying during hospitalization. Several genetic and environmental
factors affect LDL particle size, among these environmental factors
dyslipidemia, obesity and insulin resistance, all lead to increased
level of sd-LDL. Also production of sd-LDL is increased in metabolic
syndrome .This can be explained by the presence of insulin resis-
tance which is the key for pathogenesis of MetS.
8. Recommendations
 Small dense low density lipoprotein is a valuable screening tool
of CVD in patients with MetS. Its use in early screening is
admonished.
 Role of sdLDL in the risk assessment & the prevention of CVD
must be confirmed by larger prospective cohort studies and
RCTs. More studies are needed to assess the inclusion of the reference
values of sdLDL in the new guidelines which defines the meta-
bolic syndrome.
 Extensive researches are recommended to evaluate the predic-
tive role of sdLDL in other metabolic disorders such as liver dis-
ease, polycystic ovary syndrome, growth hormone deficiency,
chronic kidney disease and obstructive sleep apnea syndrome.
 The standardization of the methods of measurement of sdLDL
must be investigated by further studies taking into account
the availability & the cost of the test.
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